Reply to: What do we mean by sensitivity when we talk about detecting minimal residual disease? by Steinbach et alROSS, D. M; BRANFORD, S; MELO, J. V et al.Leukemia. 2009, Vol 23, Num 4, pp 819-820, issn 0887-6924, 2 p.Article

Enhanced sensitivity of flow cytometry for routine assessment of minimal residual diseaseDOMINGO, Esther; MORENO, Cristina; SANCHEZ-IBARROLA, Alfonso et al.Haematologica (Roma). 2010, Vol 95, Num 4, pp 691-692, issn 0390-6078, 2 p.Article

Intérêt(s) et limite(s) de l'étude de la maladie résiduelle dans la prise en charge des patients atteints de leucémie lymphoïde chronique = Interest(s) and limitation(s) of minimal residual disease studies in the management of chronic lymphocytic leukemia patientsYSEBAERT, L.Correspondances en onco-hématologie. 2012, Vol 7, Num 4, pp 198-201, issn 1954-4820, 4 p.Article

Leucémies aiguës myéloïdes = Acute myeloid leukemiaRENNEVILLE, A; DUMEZY, F; CASSINAT, B et al.Correspondances en onco-hématologie. 2012, Vol 7, Num 4, pp 218-222, issn 1954-4820, 5 p.Article

Wilms' Tumor 1 (WT1) et leucémies aiguës = Wilms' Tumor 1 (WT1) and acute leukemiaRENNEVILLE, Aline; PREUDHOMME, Claude.Hématologie (Montrouge). 2011, Vol 17, Num 1, pp 40-60, issn 1264-7527, 21 p.Article

Les marges d'exérèses dans les sarcomes des tissus mous : Les marges d'exérèse des cancers = Surgical margins in soft tissue sarcomaSTOECKLE, E; ITALIANO, A; STOCK, N et al.Bulletin du cancer. 2008, Vol 95, Num 12, pp 1199-1204, issn 0007-4551, 6 p.Article

Évaluation de la maladie résiduelle dans la leucémie lymphoïde chronique = Minimal residual disease assessment in chronic lymphocytic leukemiaMALOUM, Karim.Hématologie (Montrouge). 2006, Vol 12, Num 4, pp 274-281, issn 1264-7527, 8 p.Article

Value of minimal residual disease in patients with early cancer of the tongueULANOVSKI, David; STERN, Yoram; ROIZMAN, Pepy et al.American journal of otolaryngology. 2004, Vol 25, Num 4, pp 240-244, issn 0196-0709, 5 p.Article

Minimal Residual Disease Investigation in Haematological MalignanciesFORONI, Letizia; HOFFBRAND, Victor.Baillière's best practice & research. Clinical haematology. 2002, Vol 15, Num 1, issn 1521-6926, 233 p.Serial Issue

ADJUVANT THERAPIES AND MARKERS OF POST-SURGICAL MINIMAL RESIDUAL DISEASE. I. MARKERS AND GENERAL PROBLEMS OF CANCER ADJUVANT THERAPIES1979; RECENT RESULTS CANCER RES.; DEU; DA. 1979; NO 67; XVIII-150 P.; BIBL. DISSEM.Conference Paper

Syndromes myéloprolifératifs chromosome Philadelphie-négatifs = Minimal residual disease in chromosome Philadelphia-negative myeloproliferative neoplasmsWEMEAU, M; KILADJIAN, J. J.Correspondances en onco-hématologie. 2012, Vol 7, Num 4, pp 213-216, issn 1954-4820, 4 p.Article

Myélome multiple = Multiple myelomaHULIN, C; TARDY, S; MICHEL, J et al.Correspondances en onco-hématologie. 2012, Vol 7, Num 4, pp 204-206, issn 1954-4820, 3 p.Article

L'imàtinib (Glivec®) : une révolution dans le traitement de la leucémie myéloïde chronique (LMC)CASASSUS, Philippe.MT. Médecine thérapeutique. 2005, Vol 11, Num 6, pp 428-436, issn 1264-6520, 9 p.Article

Suivi de la maladie résiduelle dans les leucémies aiguës par cytométrie en flux = Detection of minimal residual disease in acute lymphoblastic leukaemia by flow cytometryBESBES, S; GOUIDER, E; BEN SALAH, N et al.Annales de biologie clinique (Paris). 2009, Vol 67, Num 5, pp 595-597, issn 0003-3898, 3 p.Article

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemiaBUCCISANO, Francesco; MAURILLO, Luca; DEL PRINCIPE, Maria Ilaria et al.Blood. 2012, Vol 119, Num 2, pp 332-341, issn 0006-4971, 10 p.Article

Minimal Disseminated Disease in Childhood T-Cell Lymphoblastic Lymphoma: A Report From the Children's Oncology GroupCOUSTAN-SMITH, Elaine; SANDLUND, John T; PERKINS, Sherrie L et al.Journal of clinical oncology. 2009, Vol 27, Num 21, pp 3533-3539, issn 0732-183X, 7 p.Article

Human ZMPSTE24 disease mutations: residual proteolytic activity correlates with disease severityBARROWMAN, Jemima; WILEY, Patricia A; HUDON-MILLER, Sarah E et al.Human molecular genetics (Print). 2012, Vol 21, Num 18, pp 4084-4093, issn 0964-6906, 10 p.Article

Minimal Residual Disease in Acute Lymphoblastic LeukemiaCAMPANA, Dario.Seminars in hematology. 2009, Vol 46, Num 1, pp 100-106, issn 0037-1963, 7 p.Article

Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemiaARCHAMBEAULT, Sophie; FLORES, Nikki J; ZECCA, Marco et al.Blood. 2008, Vol 111, Num 3, pp 1124-1127, issn 0006-4971, 4 p.Article

Prognostic Impact of Minimal Residual Disease in CBFB-MYH11-Positive Acute Myeloid LeukemiaCORBACIOGLU, Andrea; SCHOLL, Claudia; NACHBAUR, David et al.Journal of clinical oncology. 2010, Vol 28, Num 23, pp 3724-3729, issn 0732-183X, 6 p.Article

Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemiaMORTUZA, Forida Y; PAPAIOANNOU, Mary; MOREIRA, Ilidia M et al.Journal of clinical oncology. 2002, Vol 20, Num 4, pp 1094-1104, issn 0732-183XArticle

Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNetØSTERGAARD, M; NYVOLD, C. G; SCHNITTGER, S et al.Leukemia. 2011, Vol 25, Num 7, pp 1168-1173, issn 0887-6924, 6 p.Article

Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignanciesDIEZ-CAMPELO, Maria; PEREZ-SIMON, José Antonio; PEREZ, Jose et al.American journal of hematology. 2009, Vol 84, Num 3, pp 149-152, issn 0361-8609, 4 p.Article

Development of Minimal Residual Disease-Directed Therapy in Acute Myeloid LeukemiaFREEMAN, Sylvie D; JOVANOVIC, Jelena V; GRIMWADE, David et al.Seminars in oncology. 2008, Vol 35, Num 4, pp 388-400, issn 0093-7754, 13 p.Article

PRAME mRNA levels in cases with acute leukemia : Clinical importance and future prospectsPAYDAS, Semra; TANRIVERDI, Kahraman; YAVUZ, Sinan et al.American journal of hematology. 2005, Vol 79, Num 4, pp 257-261, issn 0361-8609, 5 p.Article